China Liver Diseases Therapeutics Market Report 2022 to 2030

China Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the China Liver Disease Therapeutics market will reach a value of $3.23 Bn from $1.85 Bn in 2022, growing at a CAGR of 7.2% during 2022-30. Liver Disease Therapeutics in China is dominated by a few domestic pharmaceutical companies such as Simcere, Beijing, and Fosun Pharma. The Liver Disease Therapeutics market in China is segmented into different types of disease and different therapy types. Some of the major factors affecting the China Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10CNPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Vishwa Modhia

Buy Now

China Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the China Liver Disease Therapeutics market will reach a value of $3.23 Bn from $1.85 Bn in 2022, growing at a CAGR of 7.2% during 2022-30.

China is an upper middle-income developing country in East Asia bordering the East China Sea, Korea Bay, and the South China Sea. According to the latest WHO data published in 2020 Liver Disease Deaths in China reached 145,603 or 1.52% of total deaths. The age-adjusted Death Rate is 7.57 per 100,000 of the population ranks China 146^th in the world. According to the International Agency for Research on Cancer's 2018 report, China has the world's ninth-highest rate of liver cancer. The prevalence of NAFLD in China was roughly 23.8 % in the early 2000s; however, the prevalence rate reached 32.9 % in 2018.

Cirrhosis is a common result of chronic liver disease, and it is believed that around 9 Mn Chinese people have cirrhosis. Early detection and prevention are critical measures for minimizing the burden of liver disease in China. In China, all babies are vaccinated against hepatitis B, and antiviral medications are available for people with chronic hepatitis B. China's government spent 5.6 % of its GDP on healthcare in 2020.

china-liver-disease-therapeutics-analysis

Market Dynamics

Market Growth Drivers Analysis

It is believed that up to 7 Mn (or 0.5 %) of the Chinese population has liver cirrhosis, which causes 460,000 new cases of liver cancer each year. China has also made a concerted effort to launch state-wide preventive measures for liver illnesses, as well as global collaborations and mentoring programmes for young hepatologists. The National Natural Science Foundation of China (NSFC), which has enabled hepatology to thrive in almost all research directions within the country, has been instrumental in such advancement. Manufacturing is highly valued in China, while the services sector is expanding due to e-commerce trends. These aspects could boost China's Liver Disease Therapeutics market.

Market Restraints

Some drugs used to treat liver disease may not be widely available in China or may be too expensive for some people. China has a big population, and access to healthcare differs across urban and rural locations. Rural communities may have limited access to specialised medical care, including treatment for liver disease. These factors may deter new entrants into the China Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Simcere Pharmaceutical Group: Simcere Pharmaceutical Group is a leading pharmaceutical company in China, with a focus on oncology, central nervous system disorders, and infectious diseases. It also produces liver disease therapeutics such as Livinex and Phospholipid
Beijing SL Pharmaceutical: Beijing SL Pharmaceutical is a research-oriented pharmaceutical company that focuses on developing and producing drugs for liver disease, such as Salinomycin and Erigeron Injection
Yabao Pharmaceutical Group: Yabao Pharmaceutical Group is a comprehensive pharmaceutical company that develops and produces drugs for a variety of therapeutic areas, including liver disease. Its liver disease products include Entecavir and Telbivudine
Fosun Pharma: Fosun Pharma is a Chinese pharmaceutical company that produces a range of therapeutics, including those for liver disease. Its liver disease products include Pegasys and Entecavir
Livzon Pharmaceutical Group Inc.: Livzon Pharmaceutical Group Inc. is a leading pharmaceutical company in China that develops and produces a wide range of therapeutic products, including those for liver disease

Recent Notable Updates

September 2022: Shanghai Fosun Pharmaceutical, a global innovation-driven pharmaceutical and healthcare industry group with deep roots in China, announced that its subsidiary Shanghai Fosun Pharmaceutical Industry Development and Jiangsu Carephar Pharmaceutical have reached an agreement for the joint development and exclusive commercialization of Keverprazan Hydrochloride by Fosun Pharmaceutical Industrial. The scope of the agreement comprises all Keverprazan Hydrochloride oral medication products and common injectable indications. The two parties will work together on a global scale.

Healthcare Policies and Reimbursement Scenarios

China has a complex regulatory and reimbursement landscape for liver therapeutics. The regulatory framework is overseen by the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE). The NMPA is responsible for the registration and approval of drugs, while the CDE evaluates the safety, efficacy, and quality of new drugs before they are approved for sale. In general, drugs that are included in the National Essential Drug List (NEDL) are more likely to be reimbursed, while newer or more expensive drugs may have limited coverage.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.